InSymbiosis Goes Live with Montrium Connect Cloud Solution Powered by Microsoft SharePoint

InSymbiosis Goes Live with Montrium Connect Cloud Solution Powered by Microsoft SharePoint
Montrium's SharePoint Powered Workspaces delivered in a validated cloud environment

January 10th 2013

Montrium (, the industry leader in strategic technology management for GxP environments in the life sciences, today announced that the validated, Cloud based Montrium Connect solution, powered by Microsoft SharePoint 2010, is now being utilized by InSymbiosis ( of Montreal, Canada.

Many life sciences organizations have expressed a desire to focus on their core competencies without the burden of managing IT and related compliance activities. Montrium Connect Cloud Solution was specifically designed to give organizations the peace of mind that their data is secure and compliant all within one validated cloud.

"Montrium Connect Cloud Solution is a major milestone in bringing Records, Quality and System Management solutions to the life sciences industry within a validated cloud (SaaS) environment.  In the past, typically only large organizations would have been able to utilize this type of system due to the high cost of implementation and demand on internal resources.  With Montrium Connect Cloud Solution, organizations of all sizes can now easily and cost-effectively benefit from this technology," said Montrium's President and CEO, Paul Fenton.  "The launch of our Records and Quality Management Workspaces with InSymbiosis are the first of many processes and activities which can be managed through Montrium Connect Cloud Solution. 

Montrium's Records Management Workspace includes eTMF and the management of other business process documents. The Quality Management Workspace, encompasses the Controlled Document Management (i.e. SOPs), Incident Management, CAPA, Audit Management, Vendor Management, Change Control and Training Management Modules."
"SharePoint 2010 provides a range of collaboration capabilities that allow life sciences organizations to connect people, insight and processes, ultimately realizing increased productivity, more efficient operations, and lower costs," said Andrea McGonigle, managing director, Microsoft Life Sciences. "By utilizing the Montrium Connect Cloud based pre-configured SharePoint workspaces, companies such as InSymbiosis can take advantage of easy-to-use content creation, management and search functionality, all while managing documents and records from a single platform." 

"We are excited to be working with Montrium and to have taken this step to enhance our Records and Quality Management processes by incorporating the Montrium Connect technology" Said Dean Wenham, President and CEO of InSymbiosis.  "This simple transition from a paper based system to electronic document management has greatly enhanced the efficiency of our collaborative drug development model where we now have a powerful environment to share information with our clients and partners as well as provide our small, virtual biopharma clients and partners with a platform in which they can reliably store, access and share their drug development documentation" 

To learn more please visit 

Montrium Inc. is a knowledge-based company focused on connecting people, processes and technology in the life sciences industry. We improve our client's Quality and R&D processes by providing strategic technology management for GxP environments, process design and optimization, GxP compliance, and Quality systems management.
Montrium's value lies in system design and content rather than software development. With a strong focus on knowledge transfer, we reduce cost and complexity by configuring standardized, 21 CFR part 11 and EU annex 11 compliant workspaces that utilize Digital signature technology and can be easily deployed within new or existing SharePoint™ environments.

If you would like more information about Montrium's dedicated and hosted workspace environments or would like to schedule an interview with a Montrium representative, please contact Valérie R. Paradis at 514.223.9153 or email her at [email protected] .

InSymbiosis is a collaborative drug development company that partners with biopharma companies to help them advance their promising drug assets towards development milestones via our unique development accelerator we call our "drug development engine".
InSymbiosis' uniqueness lies in our ability to combine a proven drug development team, an outsourcing model and access to capital. The result is that we can deliver drug development for a lower cost and faster whilst maintaining high levels of scientific integrity and regulatory compliance.

InSymbiosis works with its partners under either fee for service relationships or via risk-shared structures.
If you would like to find out more about InSymbiosis, please contact Dean Wenham at 514.807.9315 or by email at [email protected] .

Suggested Articles

Zentalis is coming out of stealth with an $85 million series C, which will propel its lead programs into pivotal trials and broaden its pipeline.

The planned takeover centers on ARQ 531, a BTK inhibitor that triggered durable responses in patients with B-cell malignancies.

At ASH, Dana-Farber researchers presented promising preclinical data on AMG 701, Amgen's long-lasting BiTE for multiple myeloma, but rivals loom.